


Date of Deposit January 31, 2001

BY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH
UNITED STATES POSTAL SERVICE BY EXPRESS MAIL POST OFFICE
ADDRESSEE SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED
AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR
PATENT & TRADEMARK OFFICE
WASHINGTON, DC, 20231.

by Ellen Fiala

OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)

SIGNATURE OF PERSON MAILING PAPER OR FEE)



#3

0400
12-28-00
AM-100151-P1
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Patent Application of:** J. P. Yardley et al.**Serial No.:** 09/706,683**Examiner:****Filed:** November 3, 2000**Group:****For:** Branched Adamantyl and Noradamantryl Aryl and
Aralkylpiperazines with Serotonin 5-HT1A Activity

Assistant Commissioner of Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)**Sir:**

With respect to the subject matter of the above-identified application, applicants have become aware of the following references which may have relevance to the examination of the invention claimed:

U.S. Patent 3,717,634, Wu (1973)

U.S. Patent 4,001,223, Sugimoto (1977)

U.S. Patent 4,202,898, Depoortere (1980)

U.S. Patent 4,797,489, Abou-Gharbia (1989)

U.S. Patent 4,873,331, Childers (1989)

U.S. Patent 4,882,432, Abou-Gharbia (1989)

U.S. Patent 4,988,814, Abou-Gharbia (1991)

U.S. Patent 5,340,812, Cliffe (1994)

U.S. Patent 5,380,725, Abou-Gharbia (1995)

U.S. Patent 5,482,940, Abou-Gharbia (1996)

U.S. Patent 5,486,518, Yardley (1996)


BEST AVAILABLE COPY

- U.S. Patent 5,519,025, Yardley (1996)
- EP 0 512 755, Cliffe 1992)
- GB 2 218 988, Abou-Gharbia (1989)
- Rasmussen, K., *Annual Reports in Med. Chemistry*,
Vol. 30, Chapter 1, Academic Press, NY, pp. 1-9 (1995)
- Schaus, J.M., *Annual Reports in Med. Chemistry*,
Vol. 33, Chapter 3., Academic Press, NY, pp. 21-30 (1998)
- Holt, W.F. et al., *Neuroprotection in CNS Diseases*, Marcel
Dekker Inc, NY pp. 87-119 (1997)
- Engelsen, B. et al., *Neurotoxicity of Excitatory Amino-Acids*,
Raven Press, NY pp. 311-322 (1990)
- Ince et al., *Rev. Contemp. Pharmacother.*, 8, 195-212 (1997)
- Meldrum, B. *Prog. Brain Res.*, 116, 441-458 (1998)
- Koroshetz & Moskowitz, *Trends in Pharmacol. Sci.*, 17, 227-233
(1996)
- Dunn, C.D.R., *Scrip Reports*, PJB Publications, Richmond 1995
Chapter Two, pp. 61-90, Chapter Four, pp 149-159
- Arrowsmith, J.E. et al., *Stroke*, 29, 2357-2362 (1998)
- DeVry, *Psychopharmacology*, 121, 1-26 (1995)
- Matsuyama, S., *Brain Res.*, 728, 175-180 (1996)
- DeVry, *Drugs of the Future*, 22, 341-349 (1997)
- Schechter et al., *Serotonin*, Vol. 2, No. 7, 299-309 (1997)

Lazareno et al., *Br. J. Pharmacol.*, 109, 1120-27 (1993)
Coyle, *Harvard Rev. Psychiatry*, 3, No. 5, 241-253 (1996)
Lucki et al., *J. Pharma. & Experimental Ther.*, 228 (No. 1)
133-139 (1983)
Smith, L.M. et al., *Pharmacol. Biochem Behavior*, 24, 1513-19,
(1986)

Copies of the above-cited references are enclosed herewith.

Respectfully submitted,


Rebecca R. Barrett
Reg. No. 35,152

Date: January 31, 2001
Telephone: (610)902-2646